Nova Mentis Life Science Corp. (NMLSF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.2 Million CAD | -37.94% |
| 2022 | 1.93 Million CAD | -33.97% |
| 2021 | 2.93 Million CAD | 62.71% |
| 2020 | 1.8 Million CAD | 47.35% |
| 2019 | 1.22 Million CAD | -65.64% |
| 2018 | 3.56 Million CAD | 97.87% |
| 2017 | 1.79 Million CAD | -8.24% |
| 2016 | 1.96 Million CAD | 178.41% |
| 2015 | 704.54 Thousand CAD | 43.44% |
| 2014 | 491.18 Thousand CAD | 160.07% |
| 2013 | 188.86 Thousand CAD | -71.37% |
| 2012 | 659.68 Thousand CAD | -33.16% |
| 2011 | 986.92 Thousand CAD | 41.25% |
| 2010 | 698.69 Thousand CAD | -62.05% |
| 2009 | 1.84 Million CAD | 144.55% |
| 2008 | 752.79 Thousand CAD | 22.57% |
| 2007 | 614.19 Thousand CAD | 503.79% |
| 2006 | 101.72 Thousand CAD | 62.16% |
| 2005 | 62.72 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 144.98 Thousand CAD | -30.94% |
| 2024 Q2 | 90.17 Thousand CAD | -37.41% |
| 2023 Q4 | 209.93 Thousand CAD | -4.16% |
| 2023 Q3 | 219.03 Thousand CAD | -27.48% |
| 2023 FY | 1.25 Million CAD | -35.09% |
| 2023 Q1 | 528 Thousand CAD | 25.26% |
| 2023 Q2 | 302.05 Thousand CAD | -42.79% |
| 2022 Q2 | 399.03 Thousand CAD | -39.73% |
| 2022 FY | 1.93 Million CAD | -33.97% |
| 2022 Q4 | 421.53 Thousand CAD | -7.27% |
| 2022 Q3 | 454.58 Thousand CAD | 13.92% |
| 2022 Q1 | 662.11 Thousand CAD | 44.17% |
| 2021 Q2 | 424.97 Thousand CAD | -31.17% |
| 2021 Q1 | 617.44 Thousand CAD | -41.67% |
| 2021 Q4 | 459.27 Thousand CAD | -67.94% |
| 2021 FY | 2.93 Million CAD | 62.71% |
| 2021 Q3 | 1.43 Million CAD | 237.05% |
| 2020 Q1 | 141.33 Thousand CAD | 3.71% |
| 2020 Q4 | 1.05 Million CAD | 119.6% |
| 2020 Q2 | 121.31 Thousand CAD | -14.17% |
| 2020 Q3 | 482.03 Thousand CAD | 297.36% |
| 2020 FY | 1.8 Million CAD | 47.35% |
| 2019 Q3 | 391.47 Thousand CAD | 8.28% |
| 2019 Q4 | 136.28 Thousand CAD | -65.19% |
| 2019 Q2 | 361.52 Thousand CAD | 8.08% |
| 2019 FY | 1.22 Million CAD | -65.64% |
| 2019 Q1 | 334.49 Thousand CAD | -33.89% |
| 2018 Q3 | 710.08 Thousand CAD | 205.17% |
| 2018 FY | 3.56 Million CAD | 97.87% |
| 2018 Q4 | 506 Thousand CAD | -28.74% |
| 2018 Q1 | 2.09 Million CAD | 162.84% |
| 2018 Q2 | 232.68 Thousand CAD | -88.89% |
| 2017 FY | 1.79 Million CAD | -8.24% |
| 2017 Q4 | 796.62 Thousand CAD | 98.1% |
| 2017 Q3 | 402.13 Thousand CAD | 20.12% |
| 2017 Q2 | 334.78 Thousand CAD | 25.77% |
| 2017 Q1 | 266.18 Thousand CAD | -83.28% |
| 2016 Q4 | 1.59 Million CAD | 720.22% |
| 2016 Q3 | 194.05 Thousand CAD | 114.01% |
| 2016 Q2 | 90.67 Thousand CAD | 6.43% |
| 2016 Q1 | 85.19 Thousand CAD | -64.39% |
| 2016 FY | 1.96 Million CAD | 178.41% |
| 2015 Q2 | 115.74 Thousand CAD | -31.56% |
| 2015 FY | 704.54 Thousand CAD | 43.44% |
| 2015 Q4 | 239.25 Thousand CAD | 32.6% |
| 2015 Q1 | 169.11 Thousand CAD | 12.9% |
| 2015 Q3 | 180.43 Thousand CAD | 55.89% |
| 2014 Q1 | 72.51 Thousand CAD | 1223.33% |
| 2014 Q2 | 137.37 Thousand CAD | 89.46% |
| 2014 FY | 491.18 Thousand CAD | 160.07% |
| 2014 Q4 | 149.78 Thousand CAD | 13.9% |
| 2014 Q3 | 131.5 Thousand CAD | -4.27% |
| 2013 Q4 | -6455.00 CAD | -107.11% |
| 2013 Q3 | 90.82 Thousand CAD | 95.57% |
| 2013 Q2 | 46.44 Thousand CAD | -19.21% |
| 2013 Q1 | 57.48 Thousand CAD | -61.32% |
| 2013 FY | 188.86 Thousand CAD | -71.37% |
| 2012 FY | 659.68 Thousand CAD | -33.16% |
| 2012 Q4 | 148.6 Thousand CAD | -29.66% |
| 2012 Q3 | 211.27 Thousand CAD | 64.05% |
| 2012 Q2 | 128.78 Thousand CAD | -20.4% |
| 2012 Q1 | 161.78 Thousand CAD | -50.13% |
| 2011 Q2 | 284.73 Thousand CAD | 60.87% |
| 2011 FY | 986.92 Thousand CAD | 41.25% |
| 2011 Q3 | 200.78 Thousand CAD | -29.48% |
| 2011 Q1 | 177 Thousand CAD | 21.73% |
| 2011 Q4 | 324.4 Thousand CAD | 61.57% |
| 2010 FY | 698.69 Thousand CAD | -62.05% |
| 2010 Q3 | 149.47 Thousand CAD | -9.81% |
| 2010 Q2 | 165.73 Thousand CAD | -30.39% |
| 2010 Q4 | 145.4 Thousand CAD | -2.72% |
| 2010 Q1 | 238.08 Thousand CAD | -40.22% |
| 2009 Q4 | 398.24 Thousand CAD | -13.41% |
| 2009 Q1 | 606.39 Thousand CAD | 218.27% |
| 2009 FY | 1.84 Million CAD | 144.55% |
| 2009 Q2 | 376.45 Thousand CAD | -37.92% |
| 2009 Q3 | 459.9 Thousand CAD | 22.17% |
| 2008 Q3 | 322.67 Thousand CAD | 71.55% |
| 2008 FY | 752.79 Thousand CAD | 22.57% |
| 2008 Q1 | 51.5 Thousand CAD | -83.48% |
| 2008 Q4 | 190.52 Thousand CAD | -40.95% |
| 2008 Q2 | 188.09 Thousand CAD | 265.2% |
| 2007 Q2 | 100.29 Thousand CAD | 0.16% |
| 2007 Q3 | 101.95 Thousand CAD | 1.65% |
| 2007 Q4 | 311.79 Thousand CAD | 205.82% |
| 2007 FY | 614.19 Thousand CAD | 503.79% |
| 2007 Q1 | 100.13 Thousand CAD | 85.59% |
| 2006 FY | 101.72 Thousand CAD | 62.16% |
| 2006 Q4 | 53.95 Thousand CAD | 211.01% |
| 2006 Q3 | 17.34 Thousand CAD | 14.08% |
| 2006 Q2 | 15.2 Thousand CAD | 0.0% |
| 2006 Q1 | - CAD | 0.0% |
| 2005 FY | 62.72 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.615% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 75.553% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.596% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 95.932% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 96.773% |
| Mesoblast Limited | 5.9 Million USD | 79.629% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 19.948% |
| Genus plc | 147.7 Million USD | 99.186% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 86.305% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 10.38% |
| Marizyme, Inc. | 19.23 Million USD | 93.751% |
| ContraFect Corporation | 56.88 Million USD | 97.887% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 85.582% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 72.729% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 18.695% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 58.772% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 56.912% |
| MultiCell Technologies, Inc. | 567.42 USD | -211788.724% |
| Accustem Sciences Inc. | 3.74 Million USD | 67.908% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.601% |
| EV Biologics, Inc. | 531.96 Thousand USD | -126.012% |
| Q BioMed Inc. | 3.43 Million USD | 65.015% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 95.135% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -208.625% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 54.242% |
| Biomind Labs Inc. | 994.18 Thousand USD | -20.933% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 99.467% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 82.103% |
| Skye Bioscience, Inc. | 13.54 Million USD | 91.125% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 41.314% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 4909.196% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 76.155% |
| IMV Inc. | 37.7 Million USD | 96.812% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 92.49% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 34.483% |
| GB Sciences, Inc. | 1.42 Million USD | 15.361% |
| Alpha Cognition Inc. | 9.7 Million USD | 87.612% |
| HST Global, Inc. | 140.9 Thousand USD | -753.257% |
| CSL Limited | 3.44 Billion USD | 99.965% |
| Halberd Corporation | 74.84 Thousand USD | -1506.45% |
| Enzolytics Inc. | 2.17 Million USD | 44.836% |
| Resverlogix Corp. | 12.71 Million USD | 90.542% |
| Affymax, Inc. | 39.38 Million USD | 96.947% |
| SYBLEU INC | 160.87 Thousand USD | -647.345% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 67.067% |
| argenx SE | 1.53 Billion USD | 99.922% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 97.907% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -15.163% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 23.874% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 64.69% |
| AVAX Technologies, Inc. | 7.31 Million USD | 83.553% |
| Zenith Capital Corp. | 8.94 Million USD | 86.556% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.854% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -6801.435% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 51.033% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -601.012% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.79% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 31.675% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | 39.033% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 35.512% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 88.936% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 37.41% |
| BioStem Technologies, Inc. | 22.97 Million USD | 94.767% |
| ONE Bio Corp. | 6.44 Million USD | 81.342% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -562.478% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | 9.969% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -6.88% |
| Agentix Corp. | 1.37 Million USD | 12.353% |
| LadRx Corporation | 3.81 Million USD | 68.458% |
| Cell Source, Inc. | 4.32 Million USD | 72.203% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -189.377% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -30.188% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -30.188% |
| NovAccess Global Inc. | 2.46 Million USD | 51.26% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 50.007% |
| Itoco Inc. | 919.14 Thousand USD | -30.807% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 71.633% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -7.444% |
| Kadimastem Ltd | 2.41 Million USD | 50.114% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -359.373% |
| CytoDyn Inc. | 18.05 Million USD | 93.342% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -4676.904% |
| Mobile Lads Corp. | 554.54 Thousand USD | -116.808% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -446.306% |
| Qrons Inc. | 643.67 Thousand USD | -86.786% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 15.319% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | 46.082% |
| Rebus Holdings, Inc. | 664 Thousand USD | -81.069% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 33.806% |
| International Stem Cell Corporation | 5.27 Million USD | 77.19% |
| Bioxytran, Inc. | 3.82 Million USD | 68.527% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -2183.916% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -5810.136% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 96.685% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 25.692% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -63.392% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 61.353% |
| Neutra Corp. | 243.82 Thousand USD | -393.107% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 93.113% |
| PureTech Health plc | 144.59 Million USD | 99.169% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 94.132% |
| IXICO plc | 4.7 Million USD | 74.457% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 86.333% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.979% |
| CSL Limited | 3.89 Billion USD | 99.969% |
| Cellectis S.A. | 97.32 Million USD | 98.765% |